Original article

Efficacy of ravuconazole in a murine model of vaginitis by Candida albicans

Mariana Elizondo-Zertuche a, Efrén Robledo-Leaf C, J. Gerardo González b, Luis A. Ceceñas b, Gloria M. González a,∗

a Universidad Autónoma de Nuevo León, UANL, Facultad de Medicina, Departamento de Microbiología, Av. Francisco I. Madero y calle Dr. E. A. Pequeño S/N, Colonia Mitras Centro, Monterrey, Nuevo León, C.P. 64460, Mexico
b Universidad Autónoma de Nuevo León, UANL, Facultad de Medicina, Hospital Universitario Dr. José Eleuterio González, Av. Francisco I. Madero y calle Dr. E. A. Pequeño S/N, Colonia Mitras Centro, Monterrey, Nuevo León, C.P. 64460, Mexico
c Universidad Autónoma de Nuevo León, UANL, Facultad de Ciencias Biológicas, Av. Universidad S/N Ciudad Universitaria, San Nicolás de los Garza, Nuevo León, C.P. 66451, Mexico

ARTICLE INFO

Article history:
Received 24 January 2013
Accepted 2 September 2013
Available online 23 September 2013

Keywords:
Vaginitis
Ravuconazole
Therapeutic efficacy
Candidiasis
Candida albicans

ABSTRACT

Background: The incidence of vulvovaginal candidiasis, a common infection among healthy women primarily caused by the yeast Candida albicans, has increased significantly in recent years.

Aims: The purpose of this study was to compare the efficacy of ravuconazole (RVC) and fluconazole (FLC) in the treatment of experimental C. albicans vaginitis.

Methods: Forty isolates of C. albicans were screened for their in vitro susceptibility to RVC and FLC. A strain of C. albicans that was resistant to FLC (minimum inhibitory concentration [MIC] of >64 μg/ml) was selected for the in vivo study. Treatment regimens for the murine vaginitis infection model were (1) 1, 5, 10, and 20 mg/kg RVC once daily, (2) 20 mg/kg RVC twice daily, (3) 20 mg/kg FLC once daily, and (4) 20 mg/kg FLC twice daily.

Results: The geometric means of the MIC values at 48 h for all isolates tested were 0.05 and 0.5 μg/ml for RVC and FLC, respectively. Regimens of either RVC or FLC at 20 mg/kg twice daily were more effective to reduce the load of FLC-resistant C. albicans than single dose administration.

Conclusions: Complete eradication of C. albicans from the vagina was not observed with RVC or FLC treatment in the animal model, although RVC treatment showed a lower fungal concentration 14 days after drug administration.

© 2013 Revista Iberoamericana de Micología. Published by Elsevier España, S.L.U. All rights reserved.

Eficacia del ravuconazol en un modelo murino de vaginitis por Candida albicans

RESUMEN

Antecedentes: En los últimos años, ha aumentado sustancialmente la incidencia de candidiasis vulvovaginal, una infección frecuente entre mujeres sanas, causada sobre todo por la levadura Candida albicans.

Objetivos: El objetivo del presente estudio fue comparar la eficacia del ravuconazol (RVC) y del fluconazol (FLC) en el tratamiento de la vaginitis experimental inducida por C. albicans.

Métodos: Se examinó la sensibilidad in vitro de 40 aislamientos de C. albicans frente a RVC y FLC. Para el estudio in vivo se seleccionó una cepa de C. albicans que fue resistente a FLC (concentración inhibitoria mínima [CMI] >64 μg/ml). Las pautas de tratamiento para el modelo murino de infección vaginal fueron 1) 1, 5, 10 y 20 mg/kg de RVC una vez al día, 2) 20 mg/kg de RVC dos veces al día, 3) 20 mg/kg de FLC una vez al día, y 4) 20 mg/kg de FLC dos veces al día.

Resultados: Para todos los aislamientos las medias geométricas de los valores de la CMI a las 48 h fueron de 0.05 y 0.5 μg/ml para RVC y FLC, respectivamente. Las pautas de 20 mg/kg de RVC o FLC dos veces al día fueron más eficaces para reducir la carga infectiva de C. albicans resistente a FLC que las administradas una vez al día.

∗ Corresponding author.
E-mail address: gmglez@yahoo.com.mx (G.M. González).

1130-1406/5 – see front matter © 2013 Revista Iberoamericana de Micología. Published by Elsevier España, S.L.U. All rights reserved.
http://dx.doi.org/10.1016/j.jriam.2013.09.006
Vulvovaginal candidiasis is an infection that affects women frequently, particularly during their childbearing years. It is caused by yeasts of the genus Candida, usually Candida albicans. C. albicans is the causative agent of vulvovaginal candidiasis in 90% of symptomatic patients, and vulvovaginal candidiasis is the second most common infection among all vaginal infections. Current treatments for Candida vulvovaginitis include a wide range of intravaginal azole preparations that are typically administered over several days, but many patients prefer the convenience of oral medications. Oral fluconazole (FLC) is a triazole with marked \emph{in vitro} activity against \emph{Candida} species. Due to its clinical efficacy and ease of administration, it is the treatment most often prescribed for this disease.

However, with the increasing incidence of vulvovaginal candidiasis caused by \emph{C. albicans} and the growing resistance of infections to conventional antifungals, especially FLC, there is a need to evaluate new therapeutic agents. Ravuconazole (RVC) is a novel triazole antifungal molecule developed by Eisai Co. Ltd. (Tokyo, Japan) that has a half-life of over 100 h, exhibits broad spectrum activity, and has a good safety profile. \emph{In vitro} studies have demonstrated potent RVC activity against \emph{Candida} spp., Cryptococcus neoformans, and other yeast species, including some strains that are not susceptible to FLC. Additional studies have demonstrated that RVC has \emph{in vitro} activity against clinical isolates of the filamentous fungi Aspergillus, Paecilomyces, Fonsecaea pedrosoi, Cladophialophora carrionii, the dimorphic fungi Coccioidoides immitis, and Histoplasma capsulatum.

Martinez et al. developed a murine model of vulvovaginal candidiasis to evaluate the therapeutic efficacy of novel antifungals for recurrent infections caused by species of \emph{Candida} resistant to conventional antifungals. RVC has been evaluated in murine and guinea pig models of infection, and has been found to be effective for the treatment of mucosal candidiasis, disseminated aspergillosis, and systemic histoplasmosis. In this study, we compared the effectiveness of RVC and FLC for the treatment of experimental \emph{C. albicans} vaginitis.

**Materials and methods**

\textit{Strains and in vitro susceptibility testing}

Forty isolates of \emph{C. albicans} from patients with vaginal infections were sent for identification to the Departamento de Microbiologia, Facultad de Medicina, Universidad Autónoma de Nuevo León, Mexico. These clinical isolates were identified by standard biochemical (API 20C AUX, Biomerieux) and microbiological procedures. They were stored in water at room temperature until use.

RVC (Eisai Co. Ltd, Tokyo, Japan) and FLC (Pfizer Inc., New York, USA) were obtained as reagent grade powders from their manufacturers. Isolates were evaluated for their \emph{in vitro} susceptibilities by the broth macrodilution method described in the Clinical and Laboratory Standards Institute reference document M27-A3. \emph{Candida parapsilosis} ATCC 22019 and \emph{Candida krusei} 6258 were included as control organisms. \emph{C. albicans} isolate 03-2718 has been used in our laboratory for previous vaginal candidiasis studies. The minimum inhibitory concentrations (MICs) of FLC and RVC for this strain were >64 \mu g/ml and 0.25 \mu g/ml, respectively. Strains were maintained on Sabouraud dextrose agar slants for short-term storage and kept in 10% glycerol at \(-70\) °C for long-term storage.

**Animal infection model**

Five week-old BALB/c mice (weight, 18 g) were purchased from Harlan Mexico. Ten mice were randomly assigned to a treatment or control group and were housed in cages containing five mice each. Food and water were provided \emph{ad libitum}. All animal research procedures were approved by the University Ethics Committee. Care, maintenance, and handling of the animals followed Mexican government licensing requirements for animal experimentation, and studies were performed in duplicate.

A previously described model of recurrent vaginal candidiasis was used. Two days prior to infection and on days 4, 11, and 18 post-challenge, mice were given 0.5 mg estradiol valerate (Delestraogen, King Pharmaceuticals) subcutaneously to maintain pseudoestrus during the entire experiment. On the day of infection, mice were anaesthetized with 80 mg/kg ketamine hydrochloride intraperitoneally and were inoculated intravaginally with 20 \mu l of a \(2 \times 10^6\) colony-forming units (CFU)/ml suspension of \emph{C. albicans} isolate 03-2718. One day after infection, the vaginal cavity of each mouse was swabbed (prior to treatment) to ensure that the infection was consistently distributed among animals. The same procedure was repeated on days 6 and 20 to evaluate treatment efficacy. Each alginic swab was placed in 0.9 ml of sterile saline, 10-fold serial dilutions were made, and 100 \mu l aliquots were plated onto Sabouraud dextrose agar plates supplemented with 0.5% (w/v) chloramphenicol to determine the CFU/ml.

Drugs were administered orally on days 1 to 5 after infection. RVC was prepared fresh daily and dissolved in 0.5% carboxymethylcellulose with 10% dimethyl sulfoxide. RVC was administered in 0.2-ml doses of 1, 5, 10, or 20 mg/kg once a day. One group of animals received a dose of 20 mg/kg twice a day. FLC was dissolved in distilled water and was administered once or twice a day in 0.2 ml doses of 20 mg/kg of body weight. Control mice were infected but received no active treatment; they received the drug vehicle containing 0.5% carboxymethylcellulose and 10% dimethyl sulfoxide orally. On day 21, mice were sacrificed by cervical dislocation.

**Statistical analysis**

Comparisons were performed using the Mann–Whitney \emph{U}-test, with significance set at a \(P\)-value < 0.05.

**Results**

**Antifungal susceptibility**

The 40 \emph{C. albicans} clinical isolates were inhibited \emph{in vitro} by 0.015–8 \mu g/ml of RVC and 0.125 to >64 \mu g/ml of FLC. The geometric means were 0.05 mg/ml and 0.5 \mu g/ml for RVC and FLC, respectively (Table 1). The concentrations that inhibited 50% of the isolates were 0.03 \mu g/ml for RVC and 0.25 \mu g/ml for FLC. RVC displayed stronger \emph{in vitro} antifungal activity at lower concentrations than FLC. The MICs of the control strains were within the acceptable ranges for the drugs tested.
RVC was administered to C. albicans isolate, as well as its efficacy during 20 days of postinfection prudeostrosis. BALB/c mice in the control group did not show a significant decrease in CFUs on days 1, 6, and 20 postinfection, confirming persistent infection in the murine model. When 20 mg/kg RVC and FLC were administered twice daily, the FLC-resistant C. albicans microbial burden was significantly reduced. RVC had a prolonged duration of efficacy because it decreased the fungal burden 15 days after treatment ended. This result can be attributed to the long half-life (>100 h) of RVC. In contrast, FLC has a short half-life of 20–50 h. The longevity of RVC makes it a viable alternative for persistent Candida infections.

RVC is currently being evaluated in clinical trials, but the results of these trials have not yet been published. To the best of our knowledge, this is the first study evaluating the efficacy of RVC against C. albicans in a murine model of vaginal infection. Our results are particularly important because they demonstrate the efficacy of RVC against candidiasis caused by a FLC-resistant C. albicans isolate. Our results also show the usefulness of orally administered RVC for the treatment of vulvovaginal candidiasis.

**Conflicts of interest**

All authors declare no conflict of interest.

**References**